Peroxisome proliferator-activated receptors (PPARs) and thyroid hormone receptors (TRs) are members of the nuclear receptor superfamily. They are ligand-dependent transcription factors that interact with their cognate hormone response elements in the promoters to regulate respective target gene expression to modulate cellular functions. While the transcription activity of each is regulated by their respective ligands, recent studies indicate that via multiple mechanisms PPARs and TRs cross-talk to affect diverse biological functions. Here we review recent advances in the understanding of the molecular mechanisms and biological impact of cross-talk between these two important nuclear receptors, focusing on their roles in adipogenesis and carcinogenesis.
Introduction
Peroxisome proliferator-activated receptors (PPARs) and thyroid hormone receptors (TRs) are ligand-dependent transcription receptors of the subfamily 1 (NR1) in the nuclear receptor superfamily. The NR1 group also includes retinoic acid receptors (RARs), Rev-erb, RARrelated orphan receptors (RORs), oxysterol receptors (LXRs), vitamin D3 receptors (VDRs), and the nuclear xenobiotic receptor CAR (constitutive androstane receptor). PPARs and TRs share a conserved DNA binding domain and exert their activity partly by heterodimerization with a common partner, the retinoid X receptor (RXR), to regulate the transcription of target genes. PPARs and TRs each have diverse effects on developmental and metabolic processes as well as in diseases such as obesity, diabetes, and cancer. The first part of this review describes current understanding of PPAR and TR biology. The second part highlights recent advances in the understanding of molecular mechanisms underlying the PPAR-TR cross-talks, with particular emphasis on the role of such cross-talk in metabolism and carcinogenesis.
hormone response element (HRE) half site (AGGTCA) with a one base-pair spacer in between (DR1) (Kliewer et al. 1992; Tugwood, et al. 1992 ).
Natural and synthetic ligands have been reported for the three PPAR isotypes (Balakumar, et al. 2007; Bensinger and Tontonoz 2008) (Table 1 & Figure 2 ). For PPARα, ligands include natural unsaturated fatty acids (FAs), leukotriene, HETEs (hydroxyeicosatetraenoic acids), and synthetic hypolipemia-inducing such as fibrates. The PPARδ ligands are less well known, but FAs have been suggested to be natural ligands for this subtype of PPAR (Fyffe, et al. 2006) . Recent studies identified a few more PPARδ agonists, namely tetradecylthioacetic acid (TTA), L-165041, and GW501516 (Berger, et al. 1999; Oliver, et al. 2001; Westergaard, et al. 2001) . For PPARγ, endogenous ligands include polyunsaturated FAs, prostanoids, and oxidized FAs found in low-density lipoproteins (LDLs) (Davies, et al. 2001; Forman, et al. 1995; Kliewer, et al. 1995) . Synthetic ligands for PPARγ include antidiabetic drugs, such as rosiglitazone and pioglitazone of the thiazolidinedione (TZD) class. This wide variety of ligands for PPARs requires a flexible plasticity in the PPAR ligand-binding domain (LBD), which is suggested by the PPARγ crystallized structure (Nolte, et al. 1998) .
PPARα is predominantly expressed in tissues with high turnover rates of FA metabolism, such as liver, brown adipose tissue (BAT), heart, and kidney. The target genes of PPARα are mainly involved in mitochondrial and peroxisomal β-oxidation of FAs and apolipoprotein synthesis. PPARδ is ubiquitously expressed in tissues. Its target genes are involved in FA oxidation, fuel switch, mitochondrial respiration, and thermogenesis (Barish, et al. 2006; Furnsinn, et al. 2007 ). PPARγ expression is mainly found in BAT and white adipose tissue (WAT) and, to a lesser extent, in the large intestine, retina, and some immune Page 4 of 34 cells (e.g., macrophage and T lymphocyte) (Harris and Phipps 2001; Ricote, et al. 1998 ).
Activation of PPARγ affects glucose metabolism and insulin sensitization. That PPARγ also has a dominant role in adipogenesis is suggested by many loss-of-function studies both in vivo and in vitro (Fajas, et al. 2001 ).
Thyroid hormone receptors
In humans, TRs are encoded by two genes, THRA and THRB, located at chromosomes 17 and 3, respectively. The THRA gene encodes three TRα (NR1A1) isoforms, TRα1, TRα2, and TRα3, which differ in their carboxyl terminus as a result of alternative splicing of the primary transcripts ( Figure 1 ). TRα1 binds T3 and activates or represses target genes, whereas TRα2 and TRα3 do not bind T3 and may antagonize T3 action (Izumo and Mahdavi 1988; Macchia, et al. 2001; Mitsuhashi, et al. 1988) . The THRA gene also yields two truncated proteins known as TR∆α1 and TR∆α2, which play a role in intestinal development (Chassande, et al. 1997; Plateroti, et al. 2001) . The THRB gene encodes two amino-terminal TRβ (NR1A2) protein variants-TRβ1 and TRβ2. In rodents, the same gene also gives rise to TRβ3 and a truncated protein TR∆β3, which lacks the DNA-binding domain (DBD) (Harvey, et al. 2007; Williams 2000) .
TRs bind to thyroid hormone response elements (TREs) in target genes as homodimers as well as heterodimers with RXR. Most naturally occurring positive TREs identified to date include 2 repeats of the half site 5'-AGGTCA-3', which is also shared by PPREs arranged as a direct repeat with 4 base pairs between the two half sites (DR4). Among known TREs, inverted repeats (also called palindromes) (e.g., GGTCATGACCTA) and everted repeats (e.g., GACCT(N 6 )AGGTCA, N: any nucleotide) have also been reported (Brent, et al. 1989; Farsetti, et al. 1992; Forman, et al. 1992; Glass, et al. 1988 ). TRs have also been shown to heterodimerize with other nuclear receptors, such as PPARs and VDRs (Bogazzi, et al. 1994; Schrader, et al. 1994 ). In the presence of PPARα, TRβ has binding affinity to a DR2 present in the myelin proteolipid protein gene promoter but not to the classical TRE, DR4, located in the malic enzyme gene. Upon thyroid hormone stimulation, the DR2-driven reporter gene is activated by the TRβ-PPARα heterodimer but not by TRα-PPARα, TRα-RXRβ or TRβ-RXRβ. Three amino acids in the D box of the DBD in TRβ are critical for this heterodimerization. The dissimilarity of the D boxes between TRβ and TRα may be responsible for this isoform-dependent protein interaction and the DNA binding sequence specificity (Bogazzi et al. 1994) . In humans, the DBDs of TRs and PPARs are highly homologous. Importantly, TRs and PPARs share the same proximal box (P-box) sequence in DBD, which is critical in sequence-specific recognition of HRE by NRs while providing contact surface with the major groove of double-stranded DNA (Nelson, et al. 1995; Rastinejad, et al. 1995) .
Triiodothyronine (T3) is the most active form of thyroid hormone in target tissues whereas L-thyroxine (T4) is the most abundant thyroid hormone in the blood. Deiodination of T4 by either type I or type II 5'-deiodinase (DI or DII) in different tissues gives rise to the more active T3 locally. Several synthetic agonists for TRs have also been developed in the past decade (Table 1) . Among them, GC-1 and KB-141 have been extensively studied and show a higher affinity to the TRβ subtype. In animal models, these TRβ-specific agonists decrease plasma cholesterol and triglyceride levels and induce fat loss without apparent adverse effects on the heart and muscles (Baxter, et al. 2004; Grover, et al. 2003 ).
Similar to PPARs, tissue-dependent distribution of TR isoforms regulates thyroid hormone actions in target organs. Both TRα and TRβ are expressed in virtually all tissues but the abundance varies for each isoform (Lazar 1993) . TRα1 is abundantly expressed in the skeletal muscle, heart, and brown adipose tissue whereas TRα2 mRNA is highly expressed in the brain. TRβ1 is more expressed in the brain, liver, and kidney. TRβ2 has a more restricted expression pattern, with major distribution in the anterior pituitary and hypothalamus (Hodin, et al. 1989 ). The isoform-dependent distribution further adds to the complexity in the regulation of T3 actions.
Cross-talk of PPARs and TRs in metabolism and adipogenesis

Reciprocal regulation between TRs and PPARs
As do PPARs, TRs also play important roles in lipid mobilization, lipid degradation, FA oxidation, and glucose metabolism. By direct or indirect effect, thyroid status influences the expression of a number of genes involved in lipid and glucose metabolism. For example, TR isoform-specific regulation of hepatic genes involved in lipogenesis and FA oxidation has been implicated by the cDNA array analysis of TRβ knockout mice treated with or without thyroid hormone (Flores-Morales, et al. 2002) . Among more than 200 hepatic genes responding to T3 treatment, approximately 60% of them are regulated by TRβ and the remaining 40% are regulated through TRα. PPARα is one of the T3-regulated genes (FloresMorales et al. 2002) .
In vivo studies reveal that TR and PPAR signaling can similarly regulate some pathways in the lipid and glucose metabolism. In corticosteroid-induced diabetic mice, a decreased thyroid hormone level is accompanied by increased serum levels of insulin, total cholesterol, triglycerides, and tissue lipid peroxidation. Interestingly, the PPARγ-agonist rosiglitazone is able to reverse the effect of dexamethasone and to increase T3 and T4 levels in circulation (Jatwa, et al. 2007 ). Moreover, in rats with a high-fat diet and in a hyperthyroid state, administration of the PPARα agonist Wy14,643 restores glucose tolerance by enhancing glucose-stimulated insulin secretion and relieves the effect of hyperthyroidism. These studies suggest that activation of PPARα activity may restore the islet function affected by abnormal T3-TR signaling (Holness, et al. 2008 ).
Cross-talk between TR and PPAR signaling pathways has also been implicated in the gene expression patterns in rats fed a high-fat diet. This diet induces an expression of the PPARα gene with a concomitant decrease in expression in the liver of RARβ, TRα1, and TRβ1. In WAT, this diet increases the expression of PPARγ2 but reduces expression of RARα, TRα1, and TRβ1 (Redonnet, et al. 2001 ). Similar results have been obtained by using a specific PPARα inducer, bezafibrate, in rats. After a 10-day treatment with bezafibrate, PPARα transcription is elevated with an activation of the downstream gene, acyl-CoA oxidase (AOX), and a decrease of maximal ligand binding capacity of RARβ and TRα1/β1 (Bonilla, et al. 2001) . However, no RXRα mRNA expression is altered by the treatment (Bonilla et al.
2001; Redonnet et al. 2001).
PPARs have been shown to affect the thyroid hormone functions in thermogenesis in vivo. Administration of the PPARγ agonist rosiglitazone to male rats shifts the energy usage to an anabolic state. Moreover, the activation of PPARγ by rosiglitazone markedly reduces plasma thyroid hormones and mRNA levels of DI and DII in the liver and BAT, respectively.
Rosiglitazone also decreases mRNA levels of the TRα1 and TRβ in BAT and the TRα1 and thermogenesis-related genes in WAT and BAT while balancing the whole body thermogenesis by down-regulating the transcription activity of TRs in these processes (Festuccia, et al. 2008 ). Regulation of DII by PPARγ activation has also been identified in skeletal muscle in which the expression of DII was found to be induced by PPARγ agonists, e.g., pioglitazone. Thus, via regulation of DII expression, PPARγ provides an additional level of regulation via modulation of thyroid hormone metabolism (Grozovsky, et al. 2009 ).
Studies of energy metabolism in rats show that the PPARδ expression is modulated by T3-TR signaling. By elevating the T3 level in hypothyroid rats, the expression of mitochondrial PPARδ in skeletal muscle is induced along with the increased mRNA level of mitochondria protein uncoupling protein 3 (UCP3) (de Lange, et al. 2007 ). More recently, in a study using transgenic mice overexpressing the putative mitochondrial T3 receptor p43 (an A/B domain truncated form of TRα1 (Casas, et al. 1999; Wrutniak-Cabello, et al. 2001 )) in skeletal muscles, an increased protein level of PPARδ was observed (Casas, et al. 2008) .
Taken together, these findings provide evidence that TR and PPAR can cross-talk by reciprocally affecting each other's activity.
Competition for the auxiliary factor RXR by PPAR and TR
It is reasonable to postulate that TRs and PPARs can regulate some common target genes involved in metabolic functions. As previously mentioned, transcriptional activities of PPARs and TRs are determined by several factors including hormone availability, relative distribution of receptor isoforms, and the abundance of the auxiliary factor, the RXR and other coregulators. On the bases of the sequence homology of hormone response elements (HREs) and the sharing of the heterodimerization partner RXR, several mechanisms have been proposed to understand the cross-signaling between PPARs and TRs.
An early study examined the effect of PPARδ on the binding of TRβ to TREs and transcription activity (Meier-Heusler, et al. 1995) . Via eletrophoretic mobility shift assay (EMSA), PPARδ was shown to reduce the binding of TRβ-RXRα to TRE, but PPARδ itself had no affinity to the TRE either as a homodimer or heterodimer with RXRα. In a chloramphenicol-acetyl-transferase (CAT) activity assay, however, PPARδ exerted an inhibitory effect on T3-induced transcription activation by TRβ on the TRE-CAT reporter gene even in the presence of overexpressed RXRα protein in cells. These results suggest that PPARδ inhibits the transcriptional activity of TR action by competing for the heterodimerized partner RXR in the nucleus (Meier-Heusler et al. 1995) .
In another report, by site-mutagenesis, a single leucine replacement by arginine at position 433 (L433R) of PPARα was shown to be critical in the inhibition of TR action. This L443R alteration abolishes heterodimerization of PPARα with RXR and consequently its selective inhibitory effect on the TR action. A mutational study also supports the idea that PPARα does not compete with TRs for binding of TREs. Mutation in the P-box of hPPARα (C122S), which destroys the DNA binding ability of PPARα, does not affect its interference with TR transactivation. These findings suggest that PPARα inhibits TRα transactivation by competing with TRα for binding to the auxiliary factor RXR .
In a similar manner as PPARs, TRs also inhibit the activity of several peroxisomal FA oxidation enzymes regulated by both of these nuclear receptors. In transgenic mice expressing luciferase under the control of promoter of the rat peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase, T3 inhibits ciprofibrate-induced luciferase activity in a TR-ependent fashion. EMSA analyses reveal that regulation of the PPAR action by TR is through competition for the available RXR. Increasing the amount of RXR in cells partially reverses the TR inhibition on PPAR action while heterodimerization-defective TR mutants lose the inhibitory activity. These results suggest that the peroxisome proliferators-and T3-signaling pathways converge through their common interaction with the heterodimeric partner RXR (Chu, et al. 1995) .
Competition for HRE binding by PPARs and TRs
In addition to competition for binding to the common heterodimeric partner (i.e., RXR), TRs compete with PPARs for binding to HREs on certain target genes. EMSA analysis shows that TRα binds to rat AOX PPRE, thus inhibiting the binding of PPAR to PPRE as PPAR/RXRα heterodimers. However, as shown by transient transfection assays, TRα stimulates transactivation by PPAR/RXRα heterodimers on the AOX-PPRE-luciferase reporter gene in a T3-independent manner with unknown mechanism (Hunter, et al. 1996) .
Moreover, comparison of reporter activity between wild type and DBD-mutated (C78S) TRα1
shows that TRα1 exerts a DBD-dependent, inhibitory effect on the PPAR-induced AOX gene transcription (Miyamoto, et al. 1997 ).
An in vivo study using mouse models also implicates an interdependent relationship between TRs and PPARs via competition for binding to HREs. Via affecting the mRNA expression levels of many genes including carnitine palmitoyl-transferase Iα (CPT-Iα), AOX, acyl-CoA dehydrogenase (ACD), male mutant mice harboring a dominant-negative P398H mutated TRα1 manifest visceral obesity, hyperleptinemia, reduced catecholamine-stimulated lipolysis in WAT, and hepatic steatosis (Liu, et al. 2007 ). In the absence of T3, wild-type TRα1 and P398H mutant significantly reduce PPARα-mediated gene transcription in CPT-PPRE-luciferase assay. However, thyroid hormone reverses the inhibition of PPARα action by wild-type TRα but not by the P398H mutant. In vitro studies suggest that the P398H mutant itself is able to bind PPRE and reduce PPARα binding to PPREs. It is not clear whether P398H mutant competes with PPARα for binding to RXR. The metabolic phenotype exhibited by P398H mutant mice is mediated in part via the unique properties of the P398H mutant receptor in interfering with PPARα signaling (Liu et al. 2007 ).
TR isoform-specific regulation of PPAR signaling in lipid metabolism
The role of TR isoforms in lipid metabolism has been recently studied in vivo using a loss-offunction approach. Mice expressing an identical mutation (denoted as PV) in the corresponding C-terminal region of TRα1 (TRα1 PV mouse; (Kaneshige, et al. 2001 )) or TRβ1
were created (TRβ PV mouse; (Kaneshige, et al. 2000) ). The PV mutation was identified in a patient with resistance to thyroid hormone (RTH) who has a frameshift mutation in the Cterminal 14 amino acids of TRβ, resulting in a complete loss of T3 binding and transcriptional capacity. This PV mutation exhibits potent dominant-negative activity. Compared with TRα1 PV mice, TRβ PV mice exhibit no reduction in white adipose mass but have significant increases in serum free FAs and total triglycerides (Ying, et al. 2007 ). The impaired adipogenesis in the white adipose tissue is mediated by the repression of the expression of PPARγ by TRα1PV, leading to the reduced expression of genes involved in lipid synthesis (Ying et al. 2007 ). Thus, in the white adipose tissue, cross-talk with PPARγ signaling is TR isoform-dependent. At present, the detailed molecular mechanisms by which TR isoforms mediate differential cross-talk with PPARγ signaling in the liver and white adipose tissue are not known. It is possible that similar to the earlier report by Bogazzi (Bogazzi, et al. 1994 ),
PPARγ could have selectivity in the heterodimerization with TRα or TRβ, resulting in differential functional consequences in lipid metabolism of these two target tissues.
Alternatively, the different co-regulatory proteins in these two target tissues could play differential modulatory roles, leading to differential regulation in lipid metabolic pathways. In view of the importance of the cross-talk of PPARγ with TRs in the regulation of lipid metabolism, these issues would merit additional studies in the future.
Cross-talk signaling of PPARs and TRs in cancers
PPARs in cancers
PPARs have been implicated in several cancers including colon cancer, thyroid cancer, and pancreatic carcinoma. However, their roles in the tumorigenesis of these cancers are controversial. Recent studies suggest that PPARδ has a role in promoting colon tumorigenesis.
Mice with PPARδ gene disruption in colonic epithelial cells have a decreased incidence of chemical carcinogen azoxymethane-induced colon tumors (Zuo, et al. 2009 ). Loss of PPARδ also suppresses the elevated expression of vascular endothelial growth factor in tumor tissue (Zuo et al. 2009 (Harman, et al. 2004 ).
PPARγ has also been proposed as a tumor suppressor in colon carcinogenesis. In primary colorectal adenocarcinomas, approximately 8% of patients contain a loss-of-function mutation in one PPARγ allele (Sarraf, et al. 1999) . PPARγ agonists can decrease premalignant intestinal lesions in rats treated with azoxymethane (Tanaka, et al. 2001) . When PPARγ is activated in primary colon tumors and colon cancer cell lines by PPARγ agonists, these cells appear to stop proliferation with reduced growth and altered morphology of increased differentiation (Sarraf, et al. 1998) . Moreover, in Pparg +/-mice with azoxymethane treatment, a greater incidence of colon cancer with an increase of β-catenin level is observed as compared with wild-type mice (Girnun, et al. 2002) . However, an oncogenic role of PPARγ in colon cancer has also been suggested in several reports. For example, activating of PPARγ signaling by treating Apc Min mice with the PPARγ ligand troglitazone increases significantly the number of colon polyps as compared with the untreated mice (Saez, et al. 1998 ).
Human pancreatic carcinoma cells express functional PPARγ that upon activation by its ligand, troglitazone, induces growth inhibition associated with G1 cell cycle arrest (Motomura, et al. 2000) . It has been further shown that p27 Kip1 can also play a key role in mediating the inhibitory effect by troglitazone (Motomura et al. 2000) . A similar effect is also observed in human pancreatic cancer cell lines by using PPARγ ligands, 15-deoxy-∆ 12,14 -prostaglandin J2 (15d-PGJ2), and ciglitazaone. That approach showed 15d-PGJ2 induces apoptosis through activation of caspases and reduces cell invasiveness by decreasing MMP-2 and MMP-9 protein levels and activity (Hashimoto, et al. 2002) . These findings raise the possibility that PPARγ as a potential therapeutic target for treatment of human pancreatic carcinomas.
The role of PPARγ in thyroid cancer was discovered by the identification of the fusion gene, the paired box 8 (PAX8)-peroxisome proliferator-activated receptor-γ (PPARγ, PAX8-PPARγ) (Kroll, et al. 2000) . Chromosomal t(2;3)(q13;p25) rearrangement results in the fusion of the thyroid transcription factor PAX8 gene to the PPARγ gene and the expression of a dominant negative form of PPARγ1 protein (PAX8-PPARγ fusion protein, PPFP). PAX8-PPARγ rearrangement occurs in 25-70% of follicular thyroid cancers (FTC) (Kroll et al. 2000) . Immortalized human thyrocytes or thyroid cancer cell lines expressing the PPFP have increased cell viability and growth (Espadinha, et al. 2007; Gregory Powell, et al. 2004 ).
Array analysis shows that the expression of PPFP in cells leads to gene expression profiles with distinct transcriptional signature. PPFP acts to up-regulation of genes associated with signal transduction, cell growth, and translational control. Concurrently, PPFP represses a large number of ribosomal protein and translational associated genes (Giordano, et al. 2006 ;
Page 15 of 34 Lacroix, et al. 2005; Lui, et al. 2005) . However, it is poorly understood how the fusion protein causes FTC.
More recently, a second PPARγ gene rearrangement, CREB3L2-PPARγ, was reported in a patient with FTC. This fusion gene encodes a CREB3L2-PPARγ fusion protein that consists of the transactivation domain of CREB3L2 and functional domains of PPARγ1.
CREB3L2-PPARγ occurs infrequently in FTC (<3% of FTC). This fusion protein induces
proliferation in primary thyroid cells, but has lost the responsiveness to the PPARγ agoniststroglitazone and rosiglitazone (Lui, et al. 2008 ).
PPARδ has also been implicated in thyroid carcinogenesis. In vivo, a higher expression level of PPARδ is associated with increased proliferation in human thyroid tumors. This increased PPARδ can be induced by thyroid mitogen (e.g., TSH and insulin) in normal primary thyrocytes that are cyclin E1-dependent ).
TRs in cancers
T3-TR signaling has also been implicated in the tumorigenesis of the liver, breast, thyroid, and colon. A variety of tumor cells respond to the stimulation of thyroid hormone to proliferate in vitro or in vivo (Esquenet, et al. 1995; Iishi, et al. 1993; Short, et al. 1980; ZhouLi, et al. 1992) . For example, thyroid hormone enhances liver cancer cell invasion by inducing the expression of furin protein, a pro-protein convertase involved in tumor cell metastasis. The FURIN gene contains putative TREs and Smad binding sites. Under stimulation by thyroid hormone or the transforming growth factor β (TGFβ), FURIN expression is induced and the increased protein level subsequently cleaves and activates matrix metalloproteinases such as MMP2 and MMP9 to increase tumor cell mobility (Chen, et al. 2008) . In xenograft models, the number of metastatic foci in liver and lung is increased with overexpression of furin in HepG2 cells. In addition, an increased T3 level in the hypothyroid severe combined immunodeficiency (SCID) mice injected with HepG2 overexpressing TRα1 (HepG2-TRα1) cells also leads to an increased number of metastatic foci in liver and lung (Chen et al. 2008 ).
An anti-tumorigenic effect of thyroid hormone has also been reported for several tumor cell types (Ledda-Columbano, et al. 1999; Martinez-Iglesias, et al. 2009 ). T3 suppresses the growth and invasiveness of several human papillary thyroid cancer cell lines overexpressing wild-type TRβ1 by inhibition of Akt and MAPK signaling pathways (Sedliarou, et al. 2007 ).
The suppression by TRβ1 of growth and invasiveness has been similarly observed in hepatocarcinoma and breast cancer cells. In responding to growth factors including epidermal growth factor, insulin-like growth factor-I, and TGFβ, the growth of hepatic and breast tumor The clinical evidence from a case-control study shows that hypothyroidism increases the risk of hepatocellular carcinoma by two-to three-fold (Hassan, et al. 2009 ). Furthermore, decreased expression of TRβ1 is also found in patients with colorectal adenoma and adenocarcinoma. Compared with normal colon epithelium, nuclear TRβ1 is less frequently detected in colorectal cancer and its precursor abnormalities (such as adenomas) (Horkko, et al. 2006) . The reduced levels of TRβ1 are also associated with the polypoid growth, presence of K-ras mutations, and more advanced stages of colorectal cancers (Horkko et al. 2006 ). In APC gene-deficient mice, Wnt/β-catenin signaling is activated with increased cyclin D1 expression (Hulit, et al. 2004) . Interestingly, in a colon carcinoma cell line SW480 with genetic mutation in the APC gene, the high transcriptional activity of cyclin D1 promoter induced by β-catinin signaling is inhibited by overexpressing TRβ1 with the presence of T3 [77] . These studies provide evidence that T3-TR signaling play key roles in carcinogenesis.
Cross-talk signaling by PPARs and TRs in carcinogenesis
Studies described in the previous sections [see Section 2.1] provide evidence that PPARs and
TRs can reciprocally inhibit transcriptional activity of the genes involved in metabolic regulation either by competing for binding to the HREs or to RXR. These mechanisms can also be extended to describe the molecular basis underlying the cross-talk signaling by PPARs and TRs in the regulation of genes involved in carcinogenesis.
Compelling evidence to indicate that PPARγ and TRβ cross-talk affects thyroid carcinogenesis is revealed in an animal model of FTC (TRβ PV/PV mice) (Suzuki, et al. 2002) .
As described in Section 2.4, the TRβ PV knockin mouse was initially created to model an inheritable disease called RTH (Kaneshige et al. 2000) . And indeed, TRβ PV mice faithfully recapitulate human RTH (Kaneshige et al. 2000) .
Remarkably, as homozygous TRβ PV (TRβ PV/PV ) mice age, they spontaneously develop FTC with a pathological progression similar to human FTC (Suzuki et al. 2002) . Consistent with the findings in human thyroid cancer (See Section 3.1), a down-regulation of the PPARγ gene in thyroid tumors of TRβ PV/PV mice is made evident by decreased mRNA and protein levels. In vitro and in vivo findings indicate that the mutated TRβPV protein acts to inhibit the ligand-dependent transcription of PPARγ by competitive binding to PPREs (Araki, et al. 2005; Ying, et al. 2003) . Cell-based transfection studies using PPRE-containing reporters indicate that TRβ1 acts to enhance the transcription activity of PPARγ in the presence of both T3 and troglitazone. TRβPV also binds to PPRE as TRβ1 does, but due to its lack of T3 binding, TRβPV acts to interfere with the enhancing effect of TRβ1 on the transcription of PPARγ (Ying et al. 2003) . Treating TRβ PV/PV mice with a PPARγ agonist, rosiglitazone, delays tumor progression and blocks metastatic spread (Kato, et al. 2006) . Moreover, when one allele of the PPARγ gene is disrupted in TRβPV mice, progression of FTC is accelerated (Kato et al. 2006) . These data suggest that the mutated TRβPV is a dominant negative 
Conclusions and Future Perspectives
Recent studies have indicated that PPARs and TRs can cross-talk to affect diverse cellular functions. Evidence presented in this review reveals three possible molecular mechanisms that may account for the cross-talk at the gene regulation level (Figure 3 ). (Bergh, et al. 2005; Gardner, et al. 2005 ). Thus the cross-talk of PPARs and TRs could also be mediated via the nongenomic actions. In view of these considerations, a rapid development in the understanding in the biological processes governed by the cross-talks of these two receptors would be forthcoming.
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